|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
Role of plasminogen activator inhibitor-1 in glucocorticoid-induced diabetes and osteopenia in mice.
|
25552599 |
2015 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
(1) The plasma PAI-1 levels of group A (60.39 ± 17.01 ng/L), group B (68.76 ± 17.81 ng/L) and group C and (68.63 ± 18.30 ng/L) are higher than that of controls (46.26 ± 26.04 ng/L); (2) Patients with genotype 4G/4G tended to exhibit higher PAI-1 level; (3) The distribution frequency of genotype 4G/4G in group C was significantly higher than in group A (42.4% vs. 28.7%, p < 0.05) and (4) In type 2 diabetic patients, the occurrence of diabetes nephropathy in genotype 4G/4G, 4G/5G and 5G/5G is 35.0%, 30.2% and 21.4%, respectively.
|
26616527 |
2016 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
Compared with 55 (33.3%) individuals in whom OSAS was not confirmed, OSAS patients had prolonged CLT (+12.8%), associated with higher PAI-1 antigen (+18.1%) (after adjustment for age, diabetes, and body mass index; both P < 0.01) and similar levels of TAFIa, plasmin, or antiplasmin.
|
27167858 |
2016 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
The aim was to evaluate tissue plasminogen activator (tPA) and plasminogen activator inhibitor type 1 (PAI-1) concentration using enzyme linked immunosorbent assay method (ELISA) in diabetic foot syndrome (DFS) as compared to a group of healthy people and patients with diabetes mellitus without symptomatic vascular complications (DM2T).
|
28193577 |
2017 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
We have previously demonstrated that a PAI-1 specific inhibitor alleviated diabetes-induced delays in skin and muscle repair.
|
29311999 |
2017 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
GeneticVariation |
BEFREE |
Low-moderate arsenic exposure was positively associated with baseline fibrinogen in participants with diabetes and unexpectedly inversely associated with PAI-1.
|
28771557 |
2017 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
From our longitudinal cohort study, we selectively recruited chronically stable HIV-infected individuals without diagnosis of diabetes mellitus at baseline (N = 62) to analyze the correlation of baseline inflammatory cytokines, including PAI-1 and whole-body insulin sensitivity, with 2-year follow-up, as measured by Matsuda Index.
|
28322572 |
2017 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
PAI-1 activity was increased in hyperlipidemic compared to healthy dogs, but there was no significant difference between dogs with hyperadrenocorticism and diabetes mellitus.
|
28266313 |
2017 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
However, inflammatory biomarkers hs-CRP [hazard ratio (HR) 1.16, (95% CI 1.05 to 1.29), p=0.005], procalcitonin [HR 1.34, (95% CI 1.07 to 1.69), p=0.012] and PAI-1 [HR 1.55, (95% CI 1.37 to 1.75), p<0.001] remained significantly associated with new-onset DM, even after multivariable adjustment for established predictors of DM.
|
29074040 |
2018 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
We recently revealed that plasminogen activator inhibitor-1 (PAI-1), a serine protease inhibitor, is involved in diabetes, osteoporosis and muscle wasting induced by glucocorticoid (GC) treatment in mice.
|
28321652 |
2018 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
PAI-1 deficiency did not affect the mRNA levels of iNOS and IL-6 in F4/80- and CD11b-double-positive cells from the bone marrow of the damaged femurs decreased by diabetes in mice.
|
29534207 |
2018 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
Compared to PBS treatment, APX3330 treatment significantly decreases plasminogen activator inhibitor type-1 (PAI-1), monocyte chemotactic protein-1 and matrix metalloproteinase 9 (MMP9) and receptor for advanced glycation endproducts expression in the ischemic brain of T1DM stroke rats.
|
29896433 |
2018 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
This study investigated PAI-1 serum level and MMP-3 activity and their correlation with glomerular filtration rate in patients with diabetes mellitus.
|
29421776 |
2018 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
Four proteins (Scavenger receptor cysteine rich type 1 protein M130, Fatty acid binding protein 4, Plasminogen activator inhibitor 1 and Insulin-like growth factor-binding protein 2) with a previously established association with incident diabetes and 3 proteins (Cathepsin D, Galectin-4, Paraoxonase type 3) with a novel association with incident diabetes.
|
30670722 |
2019 |